Latest Mammary ductal carcinoma Stories
Ductal carcinoma in situ (DCIS), a noninvasive breast cancer that some doctors are now arguing is over-treated, needs to be evaluated according to each woman’s risk, and more research is needed
During Breast Cancer Awareness Month, The Breast Milagro is sharing information that younger women need to be alert to their risk and remain vigilant about breast health. Bellingham,
Results of EORTC trial 10853 appearing in the Journal of Clinical Oncology show that breast conserving treatment combined with radiotherapy reduces the risk of local recurrence in women with ductal carcinoma in situ (DCIS).
Older women who take certain types of medication to combat high blood pressure may be putting themselves at greater risk for developing breast cancer.
After a breast cancer operation, the removed tumor is always examined, as its subtype can provide an indication of how aggressive the disease is.
A Big-Data analysis that integrates three large sets of genomic data available through The Cancer Genome Atlas has identified 37 RNA molecules that might predict survival in patients with the most common form of breast cancer.
Tomosynthesis (3D mammography) is better able to show infiltrating ductal carcinoma than 2D mammography in women at increased risk of breast cancer.
Patients with early stage breast cancer who were treated with lumpectomy plus radiation may have a better chance of survival compared with those who underwent mastectomy.
The combined loss of two tumor suppressor genes was shown to be strongly associated with progression of DCIS to invasive breast cancer.
- A bereavement by loss of parents or children; the state of being orbate; orbation.